1. Home
  2. STVN vs GRFS Comparison

STVN vs GRFS Comparison

Compare STVN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • GRFS
  • Stock Information
  • Founded
  • STVN 1949
  • GRFS 1940
  • Country
  • STVN Italy
  • GRFS Spain
  • Employees
  • STVN N/A
  • GRFS N/A
  • Industry
  • STVN Containers/Packaging
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • GRFS Health Care
  • Exchange
  • STVN Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • STVN 7.4B
  • GRFS 6.6B
  • IPO Year
  • STVN 2021
  • GRFS 2006
  • Fundamental
  • Price
  • STVN $23.98
  • GRFS $9.61
  • Analyst Decision
  • STVN Buy
  • GRFS Hold
  • Analyst Count
  • STVN 4
  • GRFS 1
  • Target Price
  • STVN $25.13
  • GRFS $10.30
  • AVG Volume (30 Days)
  • STVN 385.8K
  • GRFS 550.4K
  • Earning Date
  • STVN 11-04-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • STVN 0.27%
  • GRFS 1.47%
  • EPS Growth
  • STVN 6.78
  • GRFS 132.60
  • EPS
  • STVN 0.57
  • GRFS 0.53
  • Revenue
  • STVN $1,344,798,591.00
  • GRFS $8,744,226,659.00
  • Revenue This Year
  • STVN $8.33
  • GRFS $5.61
  • Revenue Next Year
  • STVN $10.12
  • GRFS $6.70
  • P/E Ratio
  • STVN $41.34
  • GRFS $24.41
  • Revenue Growth
  • STVN 5.28
  • GRFS 9.32
  • 52 Week Low
  • STVN $17.12
  • GRFS $6.19
  • 52 Week High
  • STVN $28.00
  • GRFS $11.14
  • Technical
  • Relative Strength Index (RSI)
  • STVN 39.23
  • GRFS 41.63
  • Support Level
  • STVN $24.81
  • GRFS $9.56
  • Resistance Level
  • STVN $27.10
  • GRFS $10.23
  • Average True Range (ATR)
  • STVN 1.33
  • GRFS 0.18
  • MACD
  • STVN -0.35
  • GRFS -0.01
  • Stochastic Oscillator
  • STVN 3.71
  • GRFS 11.85

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: